Consider Holding Febuxostat in Patients Admitted with CV Disease
We know patients with gout are already at elevated CV risk.
And early studies signaled a higher risk of CV events in patients on febuxostat compared to allopurinol...so FDA required a safety trial.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals